Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

BACKGROUND: T cells have been recognized as core effectors for cancer immunotherapy. How to restore the anti-tumor ability of suppressed T cells or improve the lethality of cytotoxic T cells has become the main focus in immunotherapy. Bispecific antibodies, especially bispecific T cell engagers (TCE...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Huilin, Wang, Hanwen, Sové, Richard J, Wang, Jun, Giragossian, Craig, Popel, Aleksander S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454244/
https://www.ncbi.nlm.nih.gov/pubmed/32859743
http://dx.doi.org/10.1136/jitc-2020-001141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454244/
https://www.ncbi.nlm.nih.gov/pubmed/32859743
http://dx.doi.org/10.1136/jitc-2020-001141

Ejemplares similares